Artelo Biosciences, Inc.
ARTL
$1.04
$0.010.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12M | 3.90M | 4.05M | 4.26M | 4.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.11M | 9.54M | 10.96M | 10.23M | 9.93M |
| Operating Income | -10.11M | -9.54M | -10.96M | -10.23M | -9.93M |
| Income Before Tax | -9.83M | -9.12M | -10.44M | -9.60M | -9.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.83 | -9.12 | -10.44 | -9.60 | -9.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.83M | -9.12M | -10.44M | -9.60M | -9.29M |
| EBIT | -10.11M | -9.54M | -10.96M | -10.23M | -9.93M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.04 | -2.85 | -3.33 | -3.13 | -3.12 |
| Normalized Basic EPS | -1.96 | -1.86 | -2.18 | -2.09 | -2.08 |
| EPS Diluted | -3.05 | -2.85 | -3.33 | -3.14 | -3.12 |
| Normalized Diluted EPS | -1.96 | -1.86 | -2.18 | -2.09 | -2.08 |
| Average Basic Shares Outstanding | 12.91M | 12.83M | 12.55M | 12.18M | 11.84M |
| Average Diluted Shares Outstanding | 12.91M | 12.83M | 12.55M | 12.18M | 11.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |